This clinical trial aims to evaluate the safety and efficacy of REGEND001, an autologous bronchial basal cell therapy, for the treatment of Chronic Obstructive Pulmonary Disease (COPD). COPD is a chronic respiratory condition characterized by persistent airflow limitation and impaired lung function, leading to significant morbidity and mortality worldwide. Current treatments primarily focus on symptom management and have limited impact on disease progression or survival. This study proposes a novel approach using autologous bronchial basal cells, which have demonstrated the potential to repair damaged lung tissue and improve lung function in preclinical studies. The therapy involves the collection of bronchial basal cells via bronchial brushing, followed by their expansion and reintroduction into the patient's lungs via bronchoscopic infusion. The primary objective is to assess the improvement in lung diffusion capacity (DLCO), with secondary endpoints including changes in lung ventilation function (FEV1, FVC) and quality of life (CAT score). The study will also monitor safety, including the incidence of adverse events. Eligible participants are COPD patients aged 40-80 with moderate to severe disease. The trial includes a screening phase, cell collection, transplantation, and follow-up assessments at 4 and 24 weeks post-treatment. This study represents a promising advancement in regenerative medicine for COPD, offering a potential therapeutic option that addresses the underlying structural damage in the lungs.

Start Date01 May 2025

Sponsor / Collaborator-

NCT01060878

/ CompletedPhase 2

Phase II, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety and Tolerability of PYM50028 in Subjects With Early-stage Parkinson's Disease Administered Once Daily for 28 Weeks

A study to test the therapeutic benefit of the compound PYM50028, versus placebo, in treating early-stage Parkinson's disease. Therapeutic benefit will be assessed using the Unified Parkinson's Disease Rating Scale (UPDRS). It is hypothesised that PYM50028 will be safe and well tolerated in this study and demonstrate therapeutic benefit in this patient population.

Start Date01 Nov 2010

Sponsor / Collaborator

Phytopharm Kleka SA

NCT00875316

/ CompletedPhase 1

A Randomised, Double-blind, Multiple Dose-ascending, Placebo-controlled Study in Healthy Volunteers and Parkinson's Disease Patients to Assess the Safety, Tolerability and PK of Daily Oral Administration of Cogane™ Over One Month

Phytopharm plc is developing Cogane™ which is a new medicine for the treatment of Parkinson's disease (PD). The purpose of the study is to find out if Cogane is safe and well tolerated in both healthy volunteers and Parkinson's disease patients and to determine if there is a difference in the way that the body deals with Cogane (pharmacokinetics) between these two groups.
It is expected that the study will prove that Cogane™ is safe and well tolerated and will provide us with a pharmacokinetic profile for both subject groups.

Start Date01 Apr 2009

Sponsor / Collaborator

Phytopharm Kleka SA

100 Clinical Results associated with Sarsasapogenin

100 Translational Medicine associated with Sarsasapogenin

100 Patents (Medical) associated with Sarsasapogenin

276

Literatures (Medical) associated with Sarsasapogenin

01 Feb 2026·STEROIDS

Novel heterosteroids induce anabolic effects in human skeletal muscle cells: An integrated analysis of anabolic and catabolic signaling pathways

Article

Author: López-Bartolo, Miguel ; González-Pérez, Pedro Pablo ; Pérez-Pérez, Linda Fabiola ; Olazo-Márquez, Nadia ; Juárez, Jorge R ; Guerrero-Luna, Gabriel ; Hernández-Linares, María Guadalupe ; Cárdenas-García, Maura ; Mendoza-Montalvo, Adrián ; Bernès, Sylvain

The aim of this study was to investigate the anabolic potential of novel heterosteroids in human skeletal muscle cells. A library of new heterosteroids was synthesized by selectively modifying the A and B rings of steroidal sapogenins (diosgenin, sarsasapogenin, and hecogenin), with six library members (S1, D3, D5, D7, D8 and D13) subsequently tested in vitro. Compound selection was based on computational modeling intracellular signaling pathways regulating muscle hypertrophy and atrophy, coupled with pharmacological potential evaluation using cheminformatics tools. The anabolic activity of these compounds was evaluated in the ATCC PCS-950-010 HSkM cell line, which represents normal human skeletal muscle cells. Among the compounds tested, D5 and D7 increased protein synthesis by approximately 22 % and 14 %, respectively. Compound D8 exhibited the most pronounced effect, increasing cell proliferation by approximately 50 %. Molecular docking and microarray analyses confirmed that D8 stimulates anabolism through AKT, ERK and MAPK activation, revealing the complex interplay between MAPK, PI3K and GPCR signaling pathways in the regulation of muscle cell proliferation. These findings suggest that compounds D8, D5, and D7 warrant further investigation in the context of muscle anabolism as potential therapeutic agents for targeting muscle atrophy.

17 Jan 2026·NATURAL PRODUCT RESEARCH

Comparative HPTLC analysis of shatavarin IV, sarsasapogenin, caffeic acid, β-sitosterol and lupeol in roots and cladodes of ten Asparagus L. ssp. from North India

Article

Author: Rani, Jyoti ; Gupta, Raghbir Chand ; Kapoor, Manish ; Mawal, Pooja ; Pradhan, Saroj Kumar

In the present research, ten species of Asparagus from North India have been analysed for secondary metabolites. The quantitative study of shatavarin IV, sarsasapogenin, caffeic acid, β-sitosterol, and lupeol in the cladodes and roots of Asparagus was conducted using a validated HPTLC method. The content of sarsasapogenin was found highest in the cladodes of A. racemosus (11.20 ± 0.025 mg/g DW) and roots of A. officinalis (5.95 ± 0.024 mg/g DW). Shatavarin IV was found highest in cladodes of A. densiflorus (6.72 ± 0.02 mg/g DW) and roots of A. adscendens (4.68 ± 0.015 mg/g DW). Caffeic acid was found most abundantly in A. officinalis (65.87 ± 0.021 mg/g DW), while β-sitosterol (9.36 ± 0.004 mg/g DW) and lupeol (5.91 ± 0.004 mg/g DW) were found highest in A. falcatus among the ten species. Overall findings showed that A. adscendens, A. densiflorus, A. falcatus and A. retrofractus have also rich quantity of examined secondary metabolites as compared to commercially important species (A. officinalis).

01 Jan 2026·FOOD CHEMISTRY

Quadratic polynomial prediction model-based isotope-coded equivalent reporter ion assay: A novel single-calibration LC–MS/MS strategy for sensitive quantification of steroidal sapogenin isomers in functional foods

Article

Author: Hou, Yue-Cai ; Chen, Chu ; Qing, Lin-Sen ; Huang, Xiao-Feng

Steroidal sapogenins, as characteristic components in functional foods, face LC-MS analytical challenges including difficulty separation, low ionization efficiency, and reference standards dependence. This study developed a novel quadratic polynomial prediction model (QPM) based-isotope-coded equivalent reporter ion assay (iERIA), exemplified using tigogenin and sarsasapogenin. N-Alkylpyridinium quaternization derivatization with pyridine‑d₀/d₅ impart permanent positive charges, significantly enhancing the ionization efficiency (20-fold) and chromatographic separation (12-fold) in LC-MS analysis. A common fragment ion m/z 255.4 generated by derivatization served as an equivalent reporter ion for quantification, with key MS parameters predicted via the QPM. A simultaneous quantitative method based on a single calibration curve was established and validated in complex matrices, thereby reducing reference standard costs and workload. Notably, the initial QPM for predicting the optimal combination of declustering potential and collision energy ensures the robustness of the iERIA strategy and expands its applicability to multicomponent determination using a single calibration curve.

News (Medical) associated with Sarsasapogenin

09 Mar 2026

·www.einpresswire.com

Raya Therapeutic Announces Selection of RT1999 (Smilagenin) onto the EXPERTS-ALS Clinical Trial Platform

Positive data from EXPERTS-ALS could accelerate RT1999 towards a registration trial; RT1999 to be presented as a poster at the MDA Conference MONTREAL, QUEBEC, CANADA, March 9, 2026 / EINPresswire.com / -- Raya Therapeutic Inc. (“Raya”), a mission-driven company focused on the treatment of ALS and other neurodegenerative diseases, today announces that RT1999 (smilagenin), one of its five clinical-stage compounds from its Raya CARES pipeline , has been selected for inclusion in the EXPERTS-ALS (EXPErimental medicine Route To Success in ALS) Platform Trial led by the University of Sheffield and the University of Oxford. RT1999 is expected to dose its first patient before the end of 2026. This selection marks a significant milestone as Raya advance the development of RT1999 for the treatment of amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND). It also represents an independent scientific endorsement of the compound’s potential as a disease-modifying therapy for ALS. Raya has previously received Orphan Drug Designations (ODD) from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of ALS with RT1999. About the EXPERTS-ALS Platform Trial EXPERTS-ALS is led by Professor Chris McDermott at the University of Sheffield and Professor Martin Turner at the University of Oxford. It involves 11 clinical centres across the UK, soon to increase to 17, and is sponsored by Sheffield Teaching Hospitals NHS Foundation Trust. It is a flagship study within the broader portfolio of the UK MND Research Institute, funded by the National Institute for Health and Care Research (NIHR) and Biomedical Research Centre Capacity Building funding schemes. Patient charities MND Association, My Name‘5 Doddie Foundation, the Darby Rimmer Foundation, and medical research charity LifeArc are providing additional support. The platform assesses potential therapies through a randomized, multicenter, open-label, multi-arm trial that evaluates investigational medicines through the measurement of the blood biomarker neurofilament light chain (NfL), which is significantly elevated in ALS patients and correlates with disease progression and survival. RT1999 will be primarily evaluated to determine its impact on NfL levels. Secondary and exploratory endpoints include clinical and survival measures. About RT1999 (Smilagenin): Mechanism of Action RT1999 (smilagenin) is an investigational, orally administered, non-peptide, small-molecule drug that readily crosses the blood–brain barrier. RT1999 acts as a neurotrophic factor modulator, dynamically regulating the synthesis of key neuroprotective proteins, including glial cell line-derived neurotrophic factor (GDNF) and brain-derived neurotrophic factor (BDNF), in response to neuronal stress signals. Importantly, RT1999 does not simply elevate GDNF and BDNF indiscriminately; rather, its effects are modulatory, restoring neurotrophic factor levels under pathological conditions while preserving homeostatic balance — potentially conferring a safety advantage over continuous exogenous neurotrophic factor administration. This mechanism provides a compelling rationale for its application in ALS, where the progressive loss of upper and lower motor neurons is a hallmark of disease pathology. Strong Preclinical Evidence in ALS Models RT1999 has demonstrated meaningful neuroprotective and disease-modifying activity across multiple preclinical models relevant to ALS, including in vitro studies in primary spinal motor neurons and in vivo studies in four established rodent models of ALS. Clinical Evidence: Safety and Signals of Efficacy from Phase 2B Parkinson's Disease Trial RT1999 has previously been evaluated in a large, rigorous Phase 2B clinical trial in Parkinson’s disease (the CONFIDENT-PD study), a 28-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study enrolling 425 treatment-naïve patients with early-stage Parkinson’s disease. Although the study did not meet its primary endpoint, independent post‑hoc analyses identified clear signs of disease‑modifying activity. Using more sensitive modern statistical methods, RT1999 180 mg showed a meaningful slowing of motor and functional decline, with the strongest effects seen on pure motor symptoms. These findings provide encouraging evidence that RT1999 may slow the progression of motor neuron degeneration. RT1999 Selected for Poster Presentation at MDA 2026 Conference Additionally, Raya is pleased to announce that RT1999 (smilagenin) has been selected for a poster presentation at the upcoming 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, taking place March 8–11, 2026 in Orlando, Florida. The poster (number 497 LB) is titled: “RT1999, smilagenin, to proceed into Phase 2 clinical trial with EXPERTS-ALS” Members of the Raya team will be in attendance at the MDA conference and welcome the opportunity to discuss RT1999 and Raya’s broader pipeline with interested stakeholders, collaborators, and the ALS community. About Raya Therapeutic Raya is a mission-driven company focused on the treatment of ALS, PD and other neurodegenerative diseases, leveraging the latest techniques for the selection and development of disease-modifying therapies. The company has a robust pipeline of five distinct clinical stage compounds (Raya CARES Pipeline) that each target different pathways involved in motor neuron degeneration in ALS. The compounds were in-licensed following a rigorous selection process based on biological plausibility, clinical target engagement and functional clinical effects reflective of efficacy. This diversified approach enables the development of combination therapies, which may have a significant impact on disease progression. For more information, visit www.rayatherapeutic.com About NIHR The mission of the National Institute for Health and Care Research (NIHR) is to improve the health and wealth of the nation through research. We do this by: - Funding high quality, timely research that benefits the NHS, public health and social care; - Investing in world-class expertise, facilities and a skilled delivery workforce to translate discoveries into improved treatments and services; - Partnering with patients, service users, carers and communities, improving the relevance, quality and impact of our research; - Attracting, training and supporting the best researchers to tackle complex health and social care challenges; - Collaborating with other public funders, charities and industry to help shape a cohesive and globally competitive research system; - Funding applied global health research and training to meet the needs of the poorest people in low and middle income countries. NIHR is funded by the Department of Health and Social Care. Its work in low and middle income countries is principally funded through UK international development funding from the UK government. Anjan Aralihalli Raya Therapeutic, Inc. admin@rayatherapeutic.com Visit us on social media: LinkedIn Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Phase 2Orphan DrugClinical Result

04 Dec 2025

·www.einpresswire.com

Raya Therapeutic unveils its Raya CARES pipeline of five clinical-stage compounds

Each new chemical entity (NCE) has substantial clinical safety data and a unique mechanism of action to treat ALS, PD, and other neurodegenerative diseases. MONTREAL, QUEBEC, CANADA, December 4, 2025 / EINPresswire.com / -- Raya Therapeutic Inc., (“Raya”) a mission-driven company focused on the treatment of amyotrophic lateral sclerosis (ALS), Parkinson's Disease (PD) and other neurodegenerative diseases, announces the unveiling of its "Raya CARES" pipeline—a portfolio of five advanced clinical-stage compounds designed with differentiated mechanisms of action to address the multifactorial biology of neurodegenerative diseases. The Raya CARES pipeline includes Cutamesine, fAsudil, Rovatirelin, Epertinib and Smilagenin. It reflects Raya’s bold commitment to advancing therapies that protect neuronal health and survival. Each compound has a distinct mechanism of action, offering complementary approaches to slowing or halting disease progression. By leveraging compounds with established human safety data (each compound has completed at least Phase 2 development involving other CNS-related indications), Raya will accelerate their development. With financing, Raya expects to advance all five compounds into large Phase 2 or Phase 3 clinical trials within 12-18 months. Pipeline Overview RT1972 (Cutamesine) – Sigma-1 receptor agonist (S1RA) • RT1972 is neuroprotective by activating the sigma-1 receptor, a key regulator of endoplasmic reticulum–mitochondrial signaling. • This drug has already completed two Phase 2 trials in other CNS indications demonstrating blood-brain barrier (BBB) penetration and safety. • Raya believes that RT1972 is the most selective and potent S1RA in development and has potential in multiple indications including Parkinson’s, Alzheimer’s, Huntington’s and in other neurodegenerative and rare diseases. RT1968 (fAsudil) – ROCK (Rho-associated kinase) inhibitor • Fasudil modulates cytoskeletal dynamics, reduces neuroinflammation, and promotes axonal regeneration, targeting both neurons and glia in ALS. • By inhibiting ROCK, fasudil decreases microgliosis, enhances oligodendrocyte survival and remyelination. • Approved in Asia for cerebral vasospasm; extensive human safety record. • Demonstrated clinical proof of concept in a large Phase 2 study in people with ALS; the study results were published in The Lancet Neurology ( LINK ) in November 2024. RT2010 (Rovatirelin) – TRH (thyrotropin-releasing hormone) analog • Rovatirelin stimulates central nervous system pathways that enhance motor neuron outgrowth and provide protection. • Raya is collaborating with Shionogi & Co., Ltd. which discovered the drug and Kissei Pharmaceutical Co., Ltd. which is developing it in a Phase 3 confirmatory study in patients with spinocerebellar ataxia (SCA) that is expected to complete enrolling in March 2027. ( NCT07040137 ). RT1978 (Epertinib) – HER2/EGFR Tyrosine Kinase Inhibitor (TKI) • Originally developed as an oncology agent that completed Phase 1/2 clinical trial development, epertinib crosses the blood–brain barrier and modulates receptor tyrosine kinase signaling. • In neurodegeneration, this mechanism may promote neuronal survival through trophic signaling and stimulating autophagy as well as reducing abnormal glial activation. • Raya is collaborating with Shionogi & Co., Ltd., which discovered and initially developed the drug. RT1999 (Smilagenin) – Neurotrophic factor modulator • Orally active, non‑peptide inducer of neurotrophic factors with blood–brain barrier penetration and extensive Phase 1/2 safety data. • Enhances production of BDNF and GDNF, supporting neuronal survival and outgrowth. • Differentiated mechanism with broad potential to treat neurodegenerative disorders. • RT1999 completed Phase 2B development in Parkinson’s Disease. While the drug missed its primary endpoints, a subsequent post-hoc analysis suggested a significant slowing of the progression of motor symptoms. "The Raya CARES pipeline represents our conviction that ALS, PD and neurodegenerative diseases demand a multipronged therapeutic strategy," said Anjan Aralihalli, President & Founder of Raya Therapeutic. "In addition to advancing each compound for development in ALS and other neurodegenerative diseases, the company has identified synergistic combinations, which it will advance as subsequent life cycle management opportunities. Combination therapies will likely be necessary to fully treat heterogenous diseases such as ALS, PD and AD.” Members of the Raya management team will attend the 36th International Symposium on ALS/MND December 4-7th in San Diego, California. Members of the management team will also be available during the JP Morgan Annual Healthcare Conference January 12 – 15th, 2026 in San Francisco, California. The J.P. Morgan Healthcare Conference is the industry's leading global investment forum, bringing together international pharma and biotech companies as well as investors across the healthcare ecosystem. For more information about Raya and its innovative pipeline, visit www.rayatherapeutic.com About Raya Raya is a mission-driven company focused on the treatment of ALS, PD and other neurodegenerative diseases, leveraging the latest techniques for the selection and development of disease-modifying therapies. The company has a robust pipeline of five distinct clinical stage compounds that each target different pathways involved in motor neuron degeneration in ALS. The compounds were in-licensed following a rigorous selection process based on biological plausibility, clinical target engagement and functional clinical effects reflective of efficacy. This diversified approach enables the development of combination therapies, which may have a significant impact on disease progression. About Shionogi & Co., Ltd. Shionogi & Co., Ltd. is a leading global research-driven pharmaceutical company dedicated to bringing benefits to patients based on its corporate philosophy of "supplying the best possible medicine to protect the health and well-being of the patients we serve." Shionogi has discovered and developed novel antibiotics, medicines for HIV and influenza and currently markets medicines for infectious diseases and central nervous system disorders. Shionogi’s global pipeline includes research programs in infectious disease, pain/CNS, metabolic disorders, rare disease, oncology and stroke. For more information, please visit https://www.shionogi.com/global/en/ . About Kissei Pharmaceutical Co., Ltd. Kissei Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company based on the management philosophy “contributing to society through high-quality, innovative pharmaceutical products” and “serving society through our employees.” As a strong R&D-oriented corporation, it concentrates on providing innovative pharmaceuticals to patients worldwide. Kissei Pharmaceutical Co., Ltd. is engaged in bringing new drugs into the world through drug discovery and licensing activities in its focus fields of rare/intractable diseases, urology, and nephrology/dialysis. For more information about Kissei Pharmaceutical Co., Ltd., please visit https://www.kissei.co.jp/e_contents/ . Anjan Aralihalli Raya Therapeutic, Inc. admin@rayatherapeutic.com Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Phase 2Drug ApprovalPhase 3Clinical Result

03 Jun 2025

·www.einpresswire.com

Raya Therapeutic Announces Two Posters at the ENCALS Meeting in Turin, Italy June 3-6

Kim Staats, PhD., to present results of preclinical studies with RT1978 (Epertinib) and the combination of 2 NCEs with distinct mechanisms (RT1972 & RT1999). MONTREAL, QUEBEC, CANADA, June 3, 2025 / EINPresswire.com / -- Raya Therapeutic Inc. (“Raya”), a mission-driven company focused on the treatment of ALS and other neurodegenerative diseases, announces 2 poster presentations by Kim Staats, PhD., at the European Network to Cure ALS (ENCALS) Meeting June 3-6, 2025 in Turin, Italy. A poster entitled “Administration with RT1978 has protective effects across ALS preclinical models” will be presented by Dr. Staats on June 5th, which displays the protective effect of RT1978 in different models of ALS. This will include a survival extension in the SOD1-G93A mouse when treated with RT1978. Epertinib (RT1978), a blood-brain-barrier penetrating EGFR inhibitor, was originally discovered and developed by Shionogi & Co., Ltd., a leading pharmaceutical company based in Japan. This molecule has completed Phase 1/2 clinical development in another indication by Shionogi & Co., Ltd., and Raya is planning to develop it for ALS. A second poster entitled “The novel combination of 2 clinical-stage molecules demonstrates a beneficial effect in preclinical models of ALS” will also be presented by Dr. Staats on June 5th. This poster will display the additional benefits of co-administration of RT1972 and RT1999 in SOD1-G93A mice and primary neuronal cultures. Raya is developing these 3 novel small molecules (RT1978, RT1972 and RT1999), each of which are oral small molecules, cross the blood-brain-barrier, have been clinically tested in other indications, have favorable safety profiles, and are not yet approved for any indication. Raya aims to advance multiple drugs from its pipeline into clinical trials in 2026. This includes the clinical development of RT1978, RT1972 and RT1999 (the latter two compounds also as a combination). Members of the Raya management team will attend the ENCALS Meeting in Turin, Italy, June 3-6. https://www.encals.eu/meetings/encals-meeting-2025-turin-italy For more information about Raya and its innovative pipeline, visit www.rayatherapeutic.com About Raya Raya is a mission-driven company focused on the treatment of ALS, leveraging the latest techniques for the selection and development of disease-modifying therapies. The company has a robust pipeline of five distinct clinical stage compounds that each target different pathways involved in motor neuron degeneration seen in ALS patients. The compounds were in-licensed following a rigorous selection process based on biological plausibility, clinical target engagement and functional clinical effects reflective of efficacy. This diversified approach may enable the development of combination therapies which may have a significant impact on disease progression. To develop further combination therapies, Raya announced a strategic research collaboration with argenx on July 12, 2024: Link . This partnership explores synergistic effects of their combined drug candidates in the hope of developing more effective treatment options for ALS patients. Raya is further supported by global experts and will leverage a unique patient-friendly platform trial design offering new hope in the fight against ALS. About Shionogi & Co., Ltd. Shionogi & Co., Ltd. is a Japanese pharmaceutical company committed to discovering and developing novel medications to address global health challenges. Since its founding in 1878, Shionogi has been dedicated to improving patient lives through scientific innovation and collaboration. Contact Information for Media Inquiries: Anjan Aralihalli Raya Therapeutic, Inc. admin@rayatherapeutic.com Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

100 Deals associated with Sarsasapogenin

External Link

KEGG	Wiki	ATC	Drug Bank
-	Sarsasapogenin	-	DB05450

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Young onset Parkinson disease	Phase 2	United States	Phytopharm Kleka SA	01 Nov 2010
Young onset Parkinson disease	Phase 2	Canada	Phytopharm Kleka SA	01 Nov 2010
Young onset Parkinson disease	Phase 2	Czechia	Phytopharm Kleka SA	01 Nov 2010
Young onset Parkinson disease	Phase 2	France	Phytopharm Kleka SA	01 Nov 2010
Young onset Parkinson disease	Phase 2	Germany	Phytopharm Kleka SA	01 Nov 2010
Young onset Parkinson disease	Phase 2	Hungary	Phytopharm Kleka SA	01 Nov 2010
Young onset Parkinson disease	Phase 2	Poland	Phytopharm Kleka SA	01 Nov 2010
Young onset Parkinson disease	Phase 2	Romania	Phytopharm Kleka SA	01 Nov 2010
Young onset Parkinson disease	Phase 2	Serbia	Phytopharm Kleka SA	01 Nov 2010
Young onset Parkinson disease	Phase 2	United Kingdom	Phytopharm Kleka SA	01 Nov 2010

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis